Calithera Biosciences (CALA) Raised to “Sell” at BidaskClub
Calithera Biosciences (NASDAQ:CALA) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Friday.
A number of other analysts have also recently commented on the stock. Zacks Investment Research raised shares of Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a report on Monday, November 6th. ValuEngine cut shares of Calithera Biosciences from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, William Blair started coverage on shares of Calithera Biosciences in a report on Thursday, October 5th. They set an “outperform” rating for the company. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. Calithera Biosciences has an average rating of “Hold” and an average price target of $15.17.
Shares of Calithera Biosciences (NASDAQ:CALA) opened at $8.60 on Friday. Calithera Biosciences has a twelve month low of $3.15 and a twelve month high of $20.05.
Calithera Biosciences (NASDAQ:CALA) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.17) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.06. The business had revenue of $7.20 million for the quarter, compared to analysts’ expectations of $6.02 million. research analysts forecast that Calithera Biosciences will post -0.77 earnings per share for the current year.
In other news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $15.64, for a total value of $9,008,640.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 16.30% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC increased its stake in shares of Calithera Biosciences by 10.9% in the second quarter. Cubist Systematic Strategies LLC now owns 14,972 shares of the biotechnology company’s stock worth $222,000 after purchasing an additional 1,472 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its stake in Calithera Biosciences by 68.1% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 17,000 shares of the biotechnology company’s stock valued at $252,000 after acquiring an additional 6,885 shares in the last quarter. Wells Fargo & Company MN grew its stake in Calithera Biosciences by 25.8% during the third quarter. Wells Fargo & Company MN now owns 33,742 shares of the biotechnology company’s stock valued at $531,000 after acquiring an additional 6,910 shares in the last quarter. Legal & General Group Plc purchased a new position in Calithera Biosciences during the second quarter valued at $120,000. Finally, Teachers Retirement System of The State of Kentucky grew its stake in Calithera Biosciences by 49.2% during the second quarter. Teachers Retirement System of The State of Kentucky now owns 27,600 shares of the biotechnology company’s stock valued at $410,000 after acquiring an additional 9,100 shares in the last quarter. 72.19% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This story was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.watchlistnews.com/calithera-biosciences-cala-raised-to-sell-at-bidaskclub/1777178.html.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with Analyst Ratings Network's FREE daily email newsletter.